Evidence map›Paper›PMID 32850156›Full record

ArticleCase reports in gastrointestinal medicine2020

Poly (ADP-Ribose) Polymerase 1 Protein Expression in Normal Pancreas and Pancreatic Adenocarcinoma.

Roberto Castiglione, Aldo E Calogero, Enzo Vicari, Giovanna Calabrini, Anna Cosentino, Placido D'Agati, Filippo Fraggetta, Michele Salemi

Open access · goldAbstract readCase Reports
In one paragraph

Article in Case reports in gastrointestinal medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Roberto CastiglioneDepartment of Clinical and Experimental Medicine, University of Catania, Catania, Italy.ORCID https://orcid.org/0000-0002-2824-7481
Aldo E CalogeroDepartment of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Enzo VicariDepartment of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Giovanna CalabriniPathology Unit, Gravina Hospital, Caltagirone, Italy.
Anna CosentinoPathology Unit, Gravina Hospital, Caltagirone, Italy.
Placido D'AgatiDepartment "GF Ingrassia" Hygiene and Public Health, University of Catania, Catania, Italy.
Filippo FraggettaPathology Unit, Cannizzaro Hospital, Catania, Italy.
Michele SalemiOasi Research Institute-IRCCS, Troina, EN, Italy.
University of Catania · ITOasi Maria SS · ITOspedale Cannizzaro · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer is a most frequent cancer in Europe, and the majority of cases of cancer of the pancreas are diagnosed above the age of 65. Radical surgery is the first curative treatment of pancreatic cancer, and alternative or combined therapeutic options, in particular, consist of adjuvant or neoadjuvant chemotherapy, with or without radiotherapy. Many factors, including diet and genetics, have been implicated in the development of cancer of the pancreas. Poly (ADP-ribose) polymerase 1 (PARP-1) protein is required for translocation of the apoptosis-inducing factor (AIF) from the mitochondria to the nucleus. It is involved in programmed cell death processes. Different PARP-1 gene expression proteins have been observed in various tumors such as lung, ovarian, endometrial, skin, and glioblastoma. We evaluated the expression of PARP-1 protein in pancreatic adenocarcinoma and normal pancreas tissues by immunohistochemistry. Protein PARP-1 in the nucleus was found in all samples (normal pancreas and pancreatic adenocarcinoma tissues). No cytoplasmic staining was observed in any sample. PARP-1-positive cells resulted higher in the normal pancreas compared with the pancreas with adenocarcinoma. PARP-1 overexpression in prostate cancer tissue compared with normal prostate suggests a greater activity of PARP-1 in these tumors. These findings suggest that PARP-1 expression in prostate cancer is an attempt to trigger apoptosis in this type of tumor, similarl to that reported in other cancers. This finding suggests that PARP-1-mediated cell death pathways are inhibited in this cancer.

Identifiers

PMID32850156
PMCPMC7436278
OpenAlexW3040317173

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.